Abera Bioscience AB (NGM:ABERA)
Sweden
· Delayed Price · Currency is SEK 6.60
+0.15 (2.33%)
At close: Dec 3, 2025
Abera Bioscience AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Cash & Equivalents | 23.18 | 6.09 | 3.32 | 15.43 | 11.95 | 0.9 | Upgrade
|
| Cash & Short-Term Investments | 23.18 | 6.09 | 3.32 | 15.43 | 11.95 | 0.9 | Upgrade
|
| Cash Growth | 646.41% | 83.49% | -78.50% | 29.13% | 1224.40% | -65.97% | Upgrade
|
| Other Receivables | 1.78 | 0.65 | 0.77 | 0.77 | 0.3 | 0.18 | Upgrade
|
| Receivables | 1.78 | 0.65 | 0.77 | 0.77 | 0.3 | 0.18 | Upgrade
|
| Prepaid Expenses | 4.74 | 3.91 | 3.38 | 1.49 | 0.19 | - | Upgrade
|
| Other Current Assets | - | - | - | -0 | - | - | Upgrade
|
| Total Current Assets | 29.69 | 10.65 | 7.46 | 17.69 | 12.44 | 1.08 | Upgrade
|
| Property, Plant & Equipment | 1.29 | 1.07 | - | - | - | - | Upgrade
|
| Long-Term Deferred Charges | 1.89 | 1.89 | 1.89 | 1.89 | 1.89 | 1.89 | Upgrade
|
| Other Long-Term Assets | 1.2 | -0 | - | - | 17.05 | - | Upgrade
|
| Total Assets | 34.07 | 13.6 | 9.35 | 19.57 | 31.37 | 2.97 | Upgrade
|
| Accounts Payable | 4.88 | 1.23 | 2.2 | 1.67 | 0.99 | 0.13 | Upgrade
|
| Accrued Expenses | 0.64 | 0.95 | 1.23 | 0.97 | 1.17 | 1.36 | Upgrade
|
| Other Current Liabilities | 0.47 | 2.77 | 0.27 | 0.16 | 0.07 | 1.05 | Upgrade
|
| Total Current Liabilities | 5.99 | 4.95 | 3.69 | 2.8 | 2.22 | 2.54 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | -0 | -0 | - | Upgrade
|
| Total Liabilities | 5.99 | 4.95 | 3.69 | 2.8 | 2.22 | 2.54 | Upgrade
|
| Common Stock | 1.46 | 1.23 | 1.16 | 1.03 | 0.84 | 0.56 | Upgrade
|
| Additional Paid-In Capital | 89.73 | 68.89 | 64.86 | 59.39 | 52.49 | 14.97 | Upgrade
|
| Retained Earnings | -63.12 | -61.46 | -60.36 | -44.11 | -24.73 | -15.56 | Upgrade
|
| Comprehensive Income & Other | - | - | 0 | 0.47 | 0.56 | 0.47 | Upgrade
|
| Shareholders' Equity | 28.08 | 8.66 | 5.66 | 16.78 | 29.15 | 0.43 | Upgrade
|
| Total Liabilities & Equity | 34.07 | 13.6 | 9.35 | 19.57 | 31.37 | 2.97 | Upgrade
|
| Net Cash (Debt) | 23.18 | 6.09 | 3.32 | 15.43 | 11.95 | 0.9 | Upgrade
|
| Net Cash Growth | 646.41% | 83.49% | -78.50% | 29.13% | 1224.40% | -65.97% | Upgrade
|
| Net Cash Per Share | 1.43 | 0.39 | 0.25 | 1.32 | 1.17 | 0.13 | Upgrade
|
| Filing Date Shares Outstanding | 18.45 | 15.35 | 14.46 | 12.91 | 11.57 | 10.46 | Upgrade
|
| Total Common Shares Outstanding | 18.45 | 15.35 | 14.46 | 12.91 | 11.57 | 6.97 | Upgrade
|
| Working Capital | 23.7 | 5.7 | 3.77 | 14.89 | 10.21 | -1.46 | Upgrade
|
| Book Value Per Share | 1.52 | 0.56 | 0.39 | 1.30 | 2.52 | 0.06 | Upgrade
|
| Tangible Book Value | 28.08 | 8.66 | 5.66 | 16.78 | 29.15 | 0.43 | Upgrade
|
| Tangible Book Value Per Share | 1.52 | 0.56 | 0.39 | 1.30 | 2.52 | 0.06 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.